Genetic Technology Alert. Drug Development in Oncology Using Personalized Medicine and Companion Diagnostics; Immunotherapeutic Candidate Development for Metastatic Melanoma; Next Generation Vaccinations for Infectious Diseases

USD 250

* Required Fields

USD 250

PAY BY INVOICE

Be the first to review this product

This issue profiles drug development in oncology using personalized medicine and companion diagnostics, immunotherapeutic candidate development for metastatic melanoma, and next generation vaccinations for infectious diseases.

Table of Contents

Genetic Technology Alert. Drug Development in Oncology Using Personalized Medicine and Companion Diagnostics; Immunotherapeutic Candidate Development for Metastatic Melanoma; Next Generation Vaccinations for Infectious DiseasesIn This Issue1. DRUG DEVELOPMENT IN ONCOLOGY USING PERSONALIZED MEDICINE AND COMPANION DIAGNOSTICS2. IMMUNOTHERAPEUTIC CANDIDATE DEVELOPMENT FOR METASTATIC MELANOMA3. NEXT GENERATION VACCINATIONS FOR INFECTIOUS DISEASES4. RECENT PATENTS IN siRNA NANOPARTICLE DELIVERY




Related Research

Release Date : 19-May-17

Region : Global

Release Date : 12-May-17

Region : Global

Release Date : 12-May-17

Region : Global

Release Date : 12-May-17

Region : Global

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.